Celebrex

Celebrex (Celecoxib): A Critical Evidence-Based Review for Clinicians and Informed Patients It’s a peculiar thing, writing a monograph for a drug that’s been off patent for years. Celebrex. The name still carries a certain weight in rheumatology clinics, a mix of relief and controversy. We tend to forget, in the era of biosimilars and JAK inhibitors, just how revolutionary selective COX-2 inhibition felt in the late 1990s. The promise was seductive: the efficacy of NSAIDs without the gastric baggage.